Aankondiging • Jun 15
Heska Corporation(NasdaqCM:HSKA) dropped from NASDAQ Composite Index Heska Corporation removed Aankondiging • Jun 14
Heska Corporation Announces Board Changes Heska Corporation announced that pursuant to the Merger Agreement, at the Effective Time, all of the members of the company's board of directors (which consisted of Sharon J. Maples, David E. Sveen, Ph.D., Stephen L. Davis, Robert L. Antin, Mark F. Furlong, Dr. Joachim Hasenmaier, Scott W. Humphrey and Kevin S. Wilson) ceased to be directors of the company, and Nefertiti Greene, Giamabatista Martano and Timothy Hirsch became directors of the company. Also in connection with the Merger and as contemplated by the Merger Agreement, following the consummation of the Merger, Nefertiti Greene, Giambatista Martano, Timothy Hirsch, Keith Melman, Anthony Gedeller, Peter Kim and Chad Susie became officers of the company. Reported Earnings • May 06
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: US$0.97 loss per share (further deteriorated from US$0.97 loss in 1Q 2022). Revenue: US$62.4m (down 3.7% from 1Q 2022). Net loss: US$10.1m (loss widened 1.4% from 1Q 2022). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Price Target Changed • Apr 04
Price target increased by 22% to US$130 Up from US$106, the current price target is an average from 4 analysts. New target price is 11% above last closing price of US$117. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.92 last year. Reported Earnings • Mar 01
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$1,923 loss per share (further deteriorated from US$0.12 loss in FY 2021). Revenue: US$257.3m (up 1.4% from FY 2021). Net loss: US$19.9m (loss widened US$18.7m from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance. Aankondiging • Feb 09
Heska Corporation to Report Q4, 2022 Results on Feb 28, 2023 Heska Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 28, 2023 Aankondiging • Feb 02
Heska Corporation Announces Nancy Wisnewski Step Downs as Executive Vice President and Chief Operating Officer, Effective March 31, 2023 On January 27, 2023, Nancy Wisnewski, Ph.D., Executive Vice President, Chief Operating Officer of Heska Corporation (the “Company”), informed the Company that after more than 30 years of service, she will step down from such position effective March 31, 2023. Dr. Wisnewski will remain with the Company in the position of Chief Science Advisor to the CEO. The Company expects to prepare operational team leadership changes in advance of the transition that begins March 31, 2023. Aankondiging • Jan 04
Heska Corporation (NasdaqCM:HSKA) acquired MBio Diagnostics, Inc. Heska Corporation (NasdaqCM:HSKA) entered a definitive agreement to acquire MBio Diagnostics, Inc. for $38.7 million on September 9, 2022. The consideration includes a mix of cash and debt forgiveness, subject to working capital and other adjustments. The transaction is expected to close in the first half of 2023, subject to customary closing conditions. As per the filling on November 8, 2022, both companies board of directors approved the merger.
Heska Corporation (NasdaqCM:HSKA) acquired MBio Diagnostics, Inc. on January 3, 2023. Price Target Changed • Nov 16
Price target decreased to US$123 Down from US$142, the current price target is an average from 5 analysts. New target price is 73% above last closing price of US$70.92. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$0.11 last year. Reported Earnings • Nov 09
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: US$0.042 loss per share (improved from US$0.19 loss in 3Q 2021). Revenue: US$61.5m (up 2.1% from 3Q 2021). Net loss: US$436.0k (loss narrowed 77% from 3Q 2021). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) exceeded analyst estimates by 48%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Recent Insider Transactions Derivative • Sep 07
Executive VP & COO exercised options to buy US$880k worth of stock. On the 1st of September, Nancy Wisnewski exercised options to buy 10k shares at a strike price of around US$8.55, costing a total of US$86k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2021, Nancy's direct individual holding has increased from 54.52k shares to 71.03k. Company insiders have collectively bought US$1.5m more than they sold, via options and on-market transactions, in the last 12 months. Major Estimate Revision • Aug 18
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$1.31 to -US$1.45 per share. Revenue forecast unchanged at US$273.3m. Medical Equipment industry in the US expected to see average net income growth of 11% next year. Consensus price target broadly unchanged at US$147. Share price rose 5.4% to US$95.69 over the past week. Reported Earnings • Aug 08
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: US$0.51 loss per share (down from US$0.056 loss in 2Q 2021). Revenue: US$64.7m (flat on 2Q 2021). Net loss: US$5.25m (loss widened US$4.68m from 2Q 2021). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 374%. Over the next year, revenue is forecast to grow 16%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Major Estimate Revision • Aug 02
Consensus EPS estimates fall by 28% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$286.5m to US$282.9m. Losses expected to increase from US$0.75 per share to US$0.96. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target broadly unchanged at US$151. Share price rose 5.1% to US$90.55 over the past week. Reported Earnings • May 10
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$0.97 loss per share (down from US$0.20 profit in 1Q 2021). Revenue: US$64.8m (up 7.1% from 1Q 2021). Net loss: US$9.99m (down US$11.9m from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 471%. Over the next year, revenue is forecast to grow 15%, compared to a 9.0% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Price Target Changed • Apr 27
Price target decreased to US$195 Down from US$219, the current price target is an average from 6 analysts. New target price is 62% above last closing price of US$121. Stock is down 34% over the past year. The company is forecast to post earnings per share of US$0.19 next year compared to a net loss per share of US$0.11 last year. Recent Insider Transactions Derivative • Mar 13
Executive VP & CFO exercised options and sold US$81k worth of stock On the 7th of March, Catherine Grassman exercised options to acquire 545 shares at no cost and sold these for an average price of US$149 per share. This trade did not impact their existing holding. Since June 2021, Catherine's direct individual holding has increased from 3.97k shares to 9.54k. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Mar 04
Executive VP recently sold US$97k worth of stock On the 3rd of March, Eleanor Baker sold around 663 shares on-market at roughly US$146 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.0m more than they bought in the last 12 months. Price Target Changed • Mar 03
Price target decreased to US$199 Down from US$229, the current price target is an average from 6 analysts. New target price is 36% above last closing price of US$146. Stock is down 19% over the past year. The company is forecast to post earnings per share of US$0.20 next year compared to a net loss per share of US$0.11 last year. Reported Earnings • Mar 02
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: US$0.12 loss per share (up from US$1.66 loss in FY 2020). Revenue: US$253.7m (up 29% from FY 2020). Net loss: US$1.15m (loss narrowed 92% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Price Target Changed • Mar 01
Price target decreased to US$219 Down from US$253, the current price target is an average from 4 analysts. New target price is 54% above last closing price of US$142. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.10 next year compared to a net loss per share of US$1.66 last year. Recent Insider Transactions Derivative • Feb 24
Director exercised options to buy US$1.1m worth of stock. On the 17th of February, David Sveen exercised options to buy 9k shares at a strike price of around US$33.06, costing a total of US$283k. This transaction amounted to 26% of their direct individual holding at the time of the trade. Since March 2021, David's direct individual holding has increased from 30.69k shares to 32.74k. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 18
CEO, President & Director exercised options to buy US$5.7m worth of stock. On the 11th of February, Kevin Wilson exercised options to buy 45k shares at a strike price of around US$20.25, costing a total of US$914k. This transaction amounted to 19% of their direct individual holding at the time of the trade. Since March 2021, Kevin's direct individual holding has increased from 233.57k shares to 280.72k. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Feb 09
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.09 to -US$0.10 per share. Revenue forecast of US$251.5m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$253 unchanged from last update. Share price fell 3.9% to US$133 over the past week. Buying Opportunity • Jan 28
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 42%. The fair value is estimated to be US$163, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% per annum over the last 3 years. The company has become profitable over the last year. Major Estimate Revision • Jan 27
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.05 to -US$0.09 per share. Revenue forecast unchanged at US$251.6m. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$239 unchanged from last update. Share price fell 3.7% to US$138 over the past week. Recent Insider Transactions • Nov 29
CEO, President & Director recently bought US$173k worth of stock On the 23rd of November, Kevin Wilson bought around 1k shares on-market at roughly US$173 per share. In the last 3 months, they made an even bigger purchase worth US$179k. Kevin has been a buyer over the last 12 months, purchasing a net total of US$352k worth in shares. Recent Insider Transactions • Nov 19
CEO, President & Director recently bought US$179k worth of stock On the 15th of November, Kevin Wilson bought around 1k shares on-market at roughly US$179 per share. This was the largest purchase by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months. Price Target Changed • Nov 19
Price target decreased to US$246 Down from US$283, the current price target is an average from 4 analysts. New target price is 37% above last closing price of US$179. Stock is up 45% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$1.66 last year. Recent Insider Transactions Derivative • Nov 06
Executive VP & COO exercised options to buy US$1.9m worth of stock. On the 2nd of November, Nancy Wisnewski exercised options to buy 10k shares at a strike price of around US$6.90, costing a total of US$69k. This transaction amounted to 18% of their direct individual holding at the time of the trade. Since December 2020, Nancy's direct individual holding has increased from 51.87k shares to 54.52k. Company insiders have collectively sold US$4.8m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Nov 05
Third quarter 2021 earnings released The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$60.2m (up 6.4% from 3Q 2020). Net loss: US$1.90m (loss narrowed 64% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Recent Insider Transactions Derivative • Aug 29
CEO, President & Director notifies of intention to sell stock Kevin Wilson intends to sell 44k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of August. If the sale is conducted around the recent share price of US$272, it would amount to US$12m. For the year to December 2020, Kevin's total compensation was 35% salary and 65% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2020, Kevin's direct individual holding has increased from 229.61k shares to 233.57k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Aug 20
Independent Director exercised options and sold US$477k worth of stock On the 17th of August, Sharon Larson exercised 2k options at a strike price of around US$28.41 and sold these shares for an average price of US$267 per share. This trade did not impact their existing holding. Since March 2021, Sharon's direct individual holding has increased from 4.79k shares to 7.50k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Aug 20
Executive VP & COO recently sold US$270k worth of stock On the 18th of August, Nancy Wisnewski sold around 1k shares on-market at roughly US$270 per share. In the last 3 months, they made an even bigger sale worth US$989k. Nancy has been a seller over the last 12 months, reducing personal holdings by US$1.7m. Recent Insider Transactions Derivative • Aug 11
Executive VP & CFO exercised options and sold US$952k worth of stock On the 6th of August, Catherine Grassman exercised 5k options at a strike price of around US$69.77 and sold these shares for an average price of US$260 per share. This trade did not impact their existing holding. Since March 2021, Catherine's direct individual holding has decreased from 4.24k shares to 3.97k. Company insiders have collectively sold US$4.2m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Aug 04
Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.72 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$64.9m (up 42% from 2Q 2020). Net loss: US$567.0k (loss narrowed 91% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jun 08
Executive VP & COO recently sold US$989k worth of stock On the 4th of June, Nancy Wisnewski sold around 5k shares on-market at roughly US$198 per share. This was the largest sale by an insider in the last 3 months. Nancy has been a seller over the last 12 months, reducing personal holdings by US$1.4m. Recent Insider Transactions Derivative • May 26
Independent Director exercised options and sold US$530k worth of stock On the 24th of May, Sharon Larson exercised 3k options at a strike price of around US$28.41 and sold these shares for an average price of US$205 per share. This trade did not impact their existing holding. Since March 2021, Sharon's direct individual holding has increased from 4.79k shares to 7.50k. Company insiders have collectively sold US$5.4m more than they bought, via options and on-market transactions in the last 12 months. Executive Departure • May 12
Independent Director has left the company On the 5th of May, Bonnie Trowbridge's tenure as Independent Director ended after 6.3 years in the role. As of December 2020, Bonnie personally held 4.09k shares (US$596k worth at the time). Bonnie is the only executive to leave the company over the last 12 months. Price Target Changed • May 12
Price target increased to US$221 Up from US$205, the current price target is an average from 6 analysts. New target price is 15% above last closing price of US$191. Stock is up 146% over the past year. Major Estimate Revision • May 08
Consensus EPS estimates increase to US$0.54 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$232.9m to US$247.3m. Forecast to become profitable, with EPS estimate increasing from -US$0.48 to US$0.54. Medical Equipment industry in the US expected to see average net income growth of 28% next year. Consensus price target up from US$205 to US$213. Share price rose 9.5% to US$200 over the past week. Reported Earnings • May 07
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.70 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$60.5m (up 97% from 1Q 2020). Net income: US$1.87m (up US$7.16m from 1Q 2020). Profit margin: 3.1% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 137 percentage points per year, which is a significant difference in performance. Recent Insider Transactions Derivative • May 04
Executive VP & COO exercised options to buy US$1.4m worth of stock. On the 30th of April, Nancy Wisnewski exercised options to buy 8k shares at a strike price of around US$6.76, costing a total of US$51k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2020, Nancy's direct individual holding has increased from 48.37k shares to 51.44k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Mar 12
Executive VP & COO exercised options and sold US$78k worth of stock On the 7th of March, Nancy Wisnewski exercised options to acquire 452 shares at no cost and sold these for an average price of US$172 per share. This trade did not impact their existing holding. Since September 2020, Nancy's direct individual holding has increased from 48.37k shares to 51.87k. Company insiders have collectively sold US$5.1m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Mar 08
Analysts update estimates The 2021 consensus revenue estimate increased from US$227.3m to US$229.9m. The company's losses in 2021 are expected to worsen with analysts lowering their EPS forecasts from -US$0.34 to -US$0.48. The Medical Equipment industry in the US is expected to see an average net income growth of 20% next year. The consensus price target of US$209 was unchanged from the last update. Share price is down by 8.9% to US$172 over the past week. Is New 90 Day High Low • Feb 25
New 90-day high: US$207 The company is up 64% from its price of US$126 on 25 November 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$77.45 per share. Reported Earnings • Feb 24
Full year 2020 earnings released: US$1.52 loss per share (vs US$0.20 loss in FY 2019) The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$197.3m (up 61% from FY 2019). Net loss: US$14.4m (loss widened US$12.9m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance. Analyst Estimate Surprise Post Earnings • Feb 24
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is forecast to grow 13%, compared to a 20% growth forecast for the Medical Equipment industry in the US. Is New 90 Day High Low • Feb 02
New 90-day high: US$181 The company is up 55% from its price of US$116 on 03 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$192 per share.